|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>177</sup>Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 ([<sup>177</sup>Lu]Lu-DOTA-Exendin-4) is a potential agent for radiotherapy of insulinomas owing to its specificity towards GLP-1 (Glucagon like peptide-1) receptors over-expressed on such cancers.
|
31731177 |
2020 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like-peptide-1 (GLP) receptor analogs are the latest agents being used in the detection of insulinomas, with initial reports suggesting high sensitivity due to universal GLP1 receptor expression on these tumors.
|
29877881 |
2018 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identify five (clathrin, dynamin1, AP2, sorting nexins [SNX] SNX27, and SNX1) that increase and four (huntingtin-interacting protein 1 [HIP1], HIP14, GASP-1, and Nedd4) that decrease insulin secretion from murine insulinoma MIN6B1 cells in response to the GLP-1 analog exendin-4.
|
29284659 |
2018 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptors are ideal targets for preoperative imaging of benign insulinoma and for quantifying the beta cell mass.
|
28103285 |
2017 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiolabeled GLP-1 and its analog Exendin-4, have been employed in diabetes and insulinoma.
|
28365524 |
2017 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the usefulness of the 48-hour fasting test and insulin surrogates followed by a glucagon stimulatory test (GST) for the diagnosis of insulinoma.
|
28230660 |
2017 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a recent issue of the Biochemical Journal, Naylor et al. described how they used CRISPR technology to modulate endogenous receptor density in insulinoma cells to get the balance right for a dual incretin peptide engaging both GLP-1- and glucose-dependent insulinotropic polypeptide-receptors.
|
28008090 |
2017 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 stimulated ABA release from an insulinoma cell line and from human islets, by ∼10- and 2-fold in low and high glucose, respectively.
|
22075645 |
2012 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For comparison, the agonist (125)I-GLP-1(7-36)amide intensively labels mouse pancreatic β-cells, mouse insulinoma and human insulinomas; high affinity displacement is observed for the GLP-1(7-36)amide in all tissues; however, a 5 and 20 times lower affinity is found for exendin(9-39) in the mouse and human tissues, respectively.
|
21210113 |
2011 |
|
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, a monohormonal type of pancreatic microadenomatosis was identified that consisted of either insulinomas or glucagon-producing tumors and was not associated with MEN1 or VHL.
|
16699310 |
2006 |
|
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our experiments suggest that some positive transcription control elements, necessary for the glucagon gene transcription in insulinoma beta-TC1 cells, are localized in the -350/-1100 region of the glucagon gene.
|
7796881 |
1995 |